Tarsus Pharmaceuticals Inc (TARS)
46.65
+0.15
(+0.32%)
USD |
NASDAQ |
Nov 14, 16:00
46.49
-0.16
(-0.34%)
After-Hours: 20:00
Tarsus Pharmaceuticals Revenue (Quarterly): 40.81M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 40.81M |
| March 31, 2024 | 27.61M |
| December 31, 2023 | 13.08M |
| September 30, 2023 | 1.871M |
| June 30, 2023 | |
| March 31, 2023 | 2.50M |
| December 31, 2022 | 10.00M |
| Date | Value |
|---|---|
| September 30, 2022 | |
| June 30, 2022 | 15.28M |
| March 31, 2022 | 0.539M |
| December 31, 2021 | 0.338M |
| September 30, 2021 | 1.24M |
| June 30, 2021 | 22.02M |
| March 31, 2021 | 33.43M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.338M
Minimum
Dec 2021
40.81M
Maximum
Jun 2024
14.06M
Average
11.54M
Median
Revenue (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 141.52M |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.05M |
| IGC Pharma Inc | 0.272M |
| NovaBay Pharmaceuticals Inc | 2.40M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -33.29M |
| Total Expenses (Quarterly) | 74.12M |
| EPS Diluted (Quarterly) | -0.88 |
| Enterprise Value | 1.517B |
| Gross Profit Margin (Quarterly) | 92.64% |
| Profit Margin (Quarterly) | -81.57% |
| Earnings Yield | -9.60% |
| Normalized Earnings Yield | -9.472 |